WO2003000248A1 - Composition liquide - Google Patents

Composition liquide Download PDF

Info

Publication number
WO2003000248A1
WO2003000248A1 PCT/JP2002/006240 JP0206240W WO03000248A1 WO 2003000248 A1 WO2003000248 A1 WO 2003000248A1 JP 0206240 W JP0206240 W JP 0206240W WO 03000248 A1 WO03000248 A1 WO 03000248A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid composition
acid
iron
fatty acid
acid ester
Prior art date
Application number
PCT/JP2002/006240
Other languages
English (en)
Japanese (ja)
Inventor
Takuto Takei
Kazuo Hasegawa
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Publication of WO2003000248A1 publication Critical patent/WO2003000248A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
    • A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a liquid composition containing an iron compound that reduces unpleasant taste when drinking, and can be used in the fields of medicine and food. Background art
  • Liquids containing iron compounds were difficult to drink due to the unpleasant taste derived from iron ions. This taste is similar to the taste when astringents that bind to proteins such as tannin and alum are consumed (astringent taste).
  • Japanese Patent Application Laid-Open No. 11-13636 discloses that a liquid formulation containing iron citrate, magnesium aspartate and Nichol HCO 60 (Example 3), as well as iron citrate ammonium, arginine And a liquid formulation containing Nikkor HCO 60 (Example 4).
  • Nikkor HCO 60 is a trade name of polyoxyethylene hydrogenated castor oil, but it is not described that it contributes to the improvement of astringency.
  • Japanese Patent Application Laid-Open No. H11-13992 discloses a drinking liquid composition having reduced specific bitterness of vitamin B i derivatives, such as iron ammonium citrate, L-magnesium aspartate, and L-magnesium aspartate.
  • vitamin B i derivatives such as iron ammonium citrate, L-magnesium aspartate, and L-magnesium aspartate.
  • An example (Example 12) in which arginine hydrochloride, polyoxyethylene-polyoxypropylene-glycol and polyoxyethylene hydrogenated castor oil are blended is described.
  • unpleasant tastes derived from iron ions there is no description of unpleasant tastes derived from iron ions.
  • An object of the present invention is to provide an iron compound-containing liquid composition which reduces astringent taste derived from iron ions, is easy to drink, and does not leave an unpleasant aftertaste. Disclosure of the invention
  • the present inventors have conducted intensive studies. As a result, when a surfactant is added to a liquid containing an iron compound and specific amino acids, protein aggregation by iron ions (astringency) was found to be reduced, and the astringent taste was improved. Furthermore, they have found that this effect is better when a polyglycerol fatty acid ester is blended than when polyoxyethylene hydrogenated castor oil is blended as a surfactant, and thus completed the present invention.
  • the present invention is a liquid composition containing an iron compound, an amino acid, and a polyglycerin fatty acid ester.
  • the iron compound in the present invention is a compound that generates a divalent or trivalent iron ion when dissolved in water, and includes, for example, ferrous fumarate, ferrous sulfate, iron sodium citrate, iron citrate Examples include ammonium, ferric sulfate, and ferric chloride. One or more of these iron compounds can be selected and blended.
  • the amount of the iron compound varies depending on the purpose of use of the liquid composition into which the iron compound is incorporated. In terms of nutrient intake, 0.5 to 6 Omg per day is preferable in terms of iron ion.If you consume 10 Om1 of liquid per day, the iron ion concentration will be 0.0 0.005 to 0.06 W / V%.
  • amino acids in the present invention are amino acids and salts of amino acids.
  • amino acids include glutamic acid, histidine, arginine, lysine, and aspartic acid.
  • amino acid salts include amino acids and acids (such as hydrochloric acid, sulfuric acid, and methanesulfonic acid) and bases (ammonia, sodium, potassium, calcium, and the like). Magnesium) or salts with other amino acids.
  • one or more of these amino acids can be selected and blended.
  • the amount of the amino acids is preferably 0.001 to 5 g as a daily dose.
  • the compounding ratio of the iron compound to the amino acids is 0.01 parts by mass or more, preferably 0.05 to 250 parts by mass, more preferably 0.05 part by mass with respect to 1 part by mass of the iron ion. -: L000 mass part.
  • the polydaricerin fatty acid ester in the present invention is an ester obtained by condensing polyglycerin obtained by polymerizing 4 to 20 glycerins with a fatty acid having 8 to 20 carbon atoms. Therefore, the HLB is 12 or more.
  • the compounding amount of the polyglycerin fatty acid ester is, when the iron compound is converted into iron ions, not less than 0.1 part by mass, preferably from 0.5 to 1 part by mass of the iron ions.
  • the amount is 100 parts by mass, more preferably 2.5 to 1000 parts by mass.
  • Oil components include vitamin E, derivatives of vitamin E (eg, esters of acetic acid, succinic acid, etc.), vitamin A, vitamin D, vitamins, ⁇ -oryzanol, soybean oil, medium-chain triglycerides, and linolenic. Acids and the like can be mentioned. These can be used alone or in combination of two or more. The effect can be exhibited if the compounding amount of the oil component is 0.7 parts by mass or less based on 1 part by mass of the polyglycerin fatty acid ester. If the oil component is excessively mixed, the liquid formulation is emulsified, and a stable liquid formulation cannot be obtained.
  • the pH of the liquid composition of the present invention is from 2.5 to 7.0, and preferably from 3.0 to 5.5. Liquids with a pH of less than 2.5 are difficult to drink due to strong acidity, and iron with a pH of more than 7.0 precipitates.
  • the pH of this liquid is, for example, organic acids such as citric acid, malic acid, fumaric acid, tartaric acid, lactic acid, and succinic acid; salts of these organic acids; inorganic acids such as hydrochloric acid; and inorganic bases such as sodium hydroxide. Can be adjusted by the addition of
  • liquid composition of the present invention vitamins, minerals, other amino acids, crude drugs, crude drug extracts, caffeine, royal jelly, and the like can be appropriately blended as long as the effects of the present invention are not impaired.
  • antioxidants, coloring agents, fragrances, flavoring agents, Additives such as a surfactant, a solubilizing agent, a preservative, and a sweetener can be appropriately added as long as the effects of the present invention are not impaired.
  • a nonionic surfactant other than polyglycerin fatty acid ester for example, polyoxyethylene hydrogenated castor oil, sucrose fatty acid ester, polyoxyethylene-polyoxypropylene-glycol, etc.
  • the present invention can be further improved. In some cases, effects can be achieved.
  • the method for preparing the liquid composition of the present invention is not particularly limited. Usually, after dissolving each component with an appropriate amount of purified water, adjusting the pH, adding the remaining purified water, adjusting the volume, and filtering and sterilizing as necessary to obtain the target liquid composition.
  • Examples are examples specifically showing the embodiments of the present invention
  • reference examples are examples of conventional technology corresponding to the examples
  • test examples are examples of tests that evaluate the examples and the reference examples. .
  • polyglycerin fatty acid ester those containing decaglycerin monomyristate ester and those containing decaglycerin monostearate were used in equal amounts.
  • citrate 10 mg was dissolved in an appropriate amount of water, the pH was adjusted to 4.8 with a NaOH solution (lmo1 / L), and the solution was adjusted to 100 mL with purified water.
  • ferric fumarate 0.10 g was added to 0.030 g, 0.090 g or 0.150 g of citric acid. Each was dissolved in an appropriate amount of purified water, the pH was adjusted to 4.8 with a NaOH solution (lmo1 / L), and adjusted to 10 OmL with purified water.
  • Figure 1 shows the correlation between protein aggregation and iron ion concentration.
  • This liquid composition can be applied, for example, to pharmaceuticals such as syrups and drinks, various preparations including quasi-drugs, and various drinks such as health drinks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition liquide renfermant un composé de fer, un acide aminé (un ou plusieurs composés sélectionnés dans le groupe comprenant de l'acide glutamique, de l'histidine, de l'arginine, de la lysine et de l'acide asparagique, et un sel de ces composés) et un ester de polyglycérol d'acide gras ; et un constituant lipidique. Cette composition liquide est une composition liquide qui renferme un composé de fer et qui est moins astringente, facile à boire, et qui ne laisse aucun arrière-goût désagréable dans la bouche.
PCT/JP2002/006240 2001-06-22 2002-06-21 Composition liquide WO2003000248A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001189322 2001-06-22
JP2001-189322 2001-06-22

Publications (1)

Publication Number Publication Date
WO2003000248A1 true WO2003000248A1 (fr) 2003-01-03

Family

ID=19028267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/006240 WO2003000248A1 (fr) 2001-06-22 2002-06-21 Composition liquide

Country Status (1)

Country Link
WO (1) WO2003000248A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104689327A (zh) * 2015-03-23 2015-06-10 山东北大高科华泰制药有限公司 谷维素液体组合物

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08332053A (ja) * 1995-06-06 1996-12-17 Sanei Gen F F I Inc マグネシウム塩の苦味低減方法
JPH09323931A (ja) * 1996-06-04 1997-12-16 Taisho Pharmaceut Co Ltd 塩酸ロペラミド配合液剤組成物
JPH09328429A (ja) * 1996-06-07 1997-12-22 Taisho Pharmaceut Co Ltd ビタミンｂ１誘導体配合液剤組成物
JPH111436A (ja) * 1997-06-13 1999-01-06 Taisho Pharmaceut Co Ltd 鉄分含有液剤
JPH11139992A (ja) * 1997-11-10 1999-05-25 Taisho Pharmaceut Co Ltd 飲用液組成物
JP2000044474A (ja) * 1998-07-24 2000-02-15 Taiyo Kagaku Co Ltd 水溶性ビタミン組成物
JP2000239173A (ja) * 1999-02-19 2000-09-05 Taisho Pharmaceut Co Ltd 鉄化合物含有内服液剤組成物
JP2000239156A (ja) * 1999-02-19 2000-09-05 Taisho Pharmaceut Co Ltd 鉄化合物含有内服液剤組成物
JP2000239154A (ja) * 1999-02-19 2000-09-05 Taisho Pharmaceut Co Ltd 鉄化合物含有内服液剤組成物
JP2000239153A (ja) * 1999-02-19 2000-09-05 Taisho Pharmaceut Co Ltd 鉄化合物含有内服液剤組成物
JP2002080347A (ja) * 2000-09-04 2002-03-19 Taisho Pharmaceut Co Ltd 鉄化合物配合内服液剤

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08332053A (ja) * 1995-06-06 1996-12-17 Sanei Gen F F I Inc マグネシウム塩の苦味低減方法
JPH09323931A (ja) * 1996-06-04 1997-12-16 Taisho Pharmaceut Co Ltd 塩酸ロペラミド配合液剤組成物
JPH09328429A (ja) * 1996-06-07 1997-12-22 Taisho Pharmaceut Co Ltd ビタミンｂ１誘導体配合液剤組成物
JPH111436A (ja) * 1997-06-13 1999-01-06 Taisho Pharmaceut Co Ltd 鉄分含有液剤
JPH11139992A (ja) * 1997-11-10 1999-05-25 Taisho Pharmaceut Co Ltd 飲用液組成物
JP2000044474A (ja) * 1998-07-24 2000-02-15 Taiyo Kagaku Co Ltd 水溶性ビタミン組成物
JP2000239173A (ja) * 1999-02-19 2000-09-05 Taisho Pharmaceut Co Ltd 鉄化合物含有内服液剤組成物
JP2000239156A (ja) * 1999-02-19 2000-09-05 Taisho Pharmaceut Co Ltd 鉄化合物含有内服液剤組成物
JP2000239154A (ja) * 1999-02-19 2000-09-05 Taisho Pharmaceut Co Ltd 鉄化合物含有内服液剤組成物
JP2000239153A (ja) * 1999-02-19 2000-09-05 Taisho Pharmaceut Co Ltd 鉄化合物含有内服液剤組成物
JP2002080347A (ja) * 2000-09-04 2002-03-19 Taisho Pharmaceut Co Ltd 鉄化合物配合内服液剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104689327A (zh) * 2015-03-23 2015-06-10 山东北大高科华泰制药有限公司 谷维素液体组合物
CN104689327B (zh) * 2015-03-23 2019-02-12 山东北大高科华泰制药有限公司 谷维素液体组合物

Similar Documents

Publication Publication Date Title
JP4337308B2 (ja) 液体組成物
JP5098198B2 (ja) 銅化合物配合組成物
JP4929628B2 (ja) 亜鉛含有内服液剤
JP5044957B2 (ja) 銅化合物配合組成物
JP5586816B2 (ja) 亜鉛化合物配合組成物
JP2006045216A (ja) 亜鉛含有経口投与用組成物
JP5546089B2 (ja) 亜鉛化合物配合組成物
JP2006306848A (ja) 銅化合物配合内服液用組成物
JP4929629B2 (ja) 亜鉛含有経口投与組成物
WO2003000248A1 (fr) Composition liquide
JP2000239173A (ja) 鉄化合物含有内服液剤組成物
JP3658878B2 (ja) 内服液剤
JP5181486B2 (ja) 亜鉛化合物配合経口用組成物
JP2004315441A (ja) 鉄化合物配合内服用液体組成物
JP5011776B2 (ja) 銅化合物配合組成物
JP2005035979A (ja) 鉄化合物を含む内服液剤組成物
JP2002080375A (ja) 鉄化合物配合内服液剤
JP2007246509A (ja) 銅化合物配合経口用組成物
JP4789292B2 (ja) 風味の改善された内服液剤
JP2000239153A (ja) 鉄化合物含有内服液剤組成物
JPS60199365A (ja) アミノ酸類含有組成物
JP4929589B2 (ja) 銅含有経口投与組成物
JP2005255653A (ja) 鉄化合物配合内服液剤
JPH10265369A (ja) 風味の改善された内服液剤
JP2000169385A (ja) 内服液剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase